These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 39187558)

  • 1. Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study.
    Rizzo M; Soares A; Grande E; Bamias A; Kopp RM; Lenci E; Buttner T; Salah S; Grillone F; de Carvalho IT; Tapia JC; Gucciardino C; Pinto A; Mennitto A; Abahssain H; Rescigno P; Myint Z; Takeshita H; Spinelli GP; Popovic L; Vitale MG; Fiala O; Giannatempo P; Zakopoulou R; Carrozza F; Massari F; Monteiro FSM; Pace MP; Giannini M; Roviello G; Porta C; Battelli N; Kanesvaran R; Santoni M
    Sci Rep; 2024 Aug; 14(1):19802. PubMed ID: 39187558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study.
    Santoni M; Massari F; Takeshita H; Tapia JC; Dionese M; Pichler R; Rizzo M; Lam ET; Grande E; Kemp R; Molina-Cerrillo J; Calabrò F; Tural D; Küronya Z; Kucharz J; Fiala O; Seront E; Kopp RM; Abahssain H; Kopecky J; Martignetti A; Kanesvaran R; Zakopoulou R; Ansari J; Landmesser J; Mollica V; Porta C; Bellmunt J; Salah S; Santini D
    Clin Exp Med; 2023 Dec; 23(8):5413-5422. PubMed ID: 37917218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma With Prior Avelumab
    Minato A; Furubayashi N; Tomoda T; Masaoka H; Song Y; Hori Y; Kiyoshima K; Negishi T; Kuroiwa K; Seki N; Tomisaki I; Nakamura M; Harada K; Fujimoto N
    Anticancer Res; 2024 Aug; 44(8):3419-3426. PubMed ID: 39060065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. J-AVENUE: A retrospective, real-world study evaluating patient characteristics and outcomes in patients with advanced urothelial carcinoma treated with avelumab first-line maintenance therapy in Japan.
    Kikuchi E; Hayakawa N; Nakayama M; Uno M; Nakatsu H; Kitagawa C; Miyake H; Yamada T; Fujita K; Shimoyama H; Nishihara K; Kobayashi M; Nakamura M; Fujimoto K; Sano T; Nishiyama N; Ito T; Kajita M; Kobayashi T; Kitamura H
    Int J Urol; 2024 Aug; 31(8):859-867. PubMed ID: 38722221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial.
    Nishiyama H; Yamamoto Y; Sassa N; Nishimura K; Fujimoto K; Fukasawa S; Yokoyama M; Enokida H; Takahashi K; Tanaka Y; Imai K; Shimamoto T; Perini R; Frenkl T; Bajorin D; Bellmunt J
    Int J Clin Oncol; 2020 Jan; 25(1):165-174. PubMed ID: 31729625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study.
    Massari F; Santoni M; Takeshita H; Okada Y; Tapia JC; Basso U; Maruzzo M; Scagliarini S; Büttner T; Fornarini G; Myint ZW; Galli L; Souza VC; Pichler R; De Giorgi U; Gandur N; Lam ET; Gilbert D; Popovic L; Grande E; Mammone G; Berardi R; Crabb SJ; Kemp R; Molina-Cerrillo J; Freitas M; Luz M; Iacovelli R; Calabrò F; Tural D; Atzori F; Küronya Z; Chiari R; Campos S; Caffo O; Fay AP; Kucharz J; Zucali PA; Rinck JA; Zeppellini A; Bastos DA; Aurilio G; Mota A; Trindade K; Ortega C; Sade JP; Rizzo M; Fiala O; Vau N; Giannatempo P; Barillas A; Monteiro FSM; Dauster B; Mennitto A; Nogueira L; de Carvalho Fernandes R; Seront E; Aceituno LG; Grillone F; Cutuli HJ; Fernandez M; Bassanelli M; Kopp RM; Roviello G; Abahssain H; Procopio G; Milella M; Kopecky J; Martignetti A; Messina C; Caitano M; Inman E; Kanesvaran R; Herchhorn D; Santini D; Bamias A; Bisonni R; Mosca A; Morelli F; Maluf F; Soares A; Nunes F; Pinto A; Zgura A; Incorvaia L; Ansari J; Zabalza IO; Landmesser J; Rizzo A; Mollica V; Marchetti A; Rosellini M; Sorgentoni G; Battelli N; Buti S; Porta C; Bellmunt J
    Cancer Immunol Immunother; 2024 Apr; 73(6):106. PubMed ID: 38634928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Evidence of Tumor and Patient Characteristics and Survival with Avelumab Maintenance after Chemotherapy for Advanced and Metastatic Urothelial Carcinoma.
    Banek S; Wenzel M; Lauer B; Le QC; Hoeh B; Koll F; Cano Garcia C; Humke C; Köllermann J; Chun FKH; Kosiba M; Kluth LA
    Urol Int; 2024; 108(4):285-291. PubMed ID: 38447555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gustave Roussy Immune score as a prognostic biomarker in patients with platinum-refractory metastatic urothelial carcinoma treated with pembrolizumab: YUSHIMA study.
    Tanabe K; Kobayashi S; Maezawa Y; Ishihara K; Inoue N; Izumi K; Fujiwara M; Toide M; Yamamoto T; Uehara S; Araki S; Inoue M; Takazawa R; Numao N; Ohtsuka Y; Tanaka H; Yoshida S; Fujii Y
    Int J Clin Oncol; 2024 Sep; 29(9):1302-1310. PubMed ID: 38833113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real-world data.
    Uemura K; Ito H; Jikuya R; Kondo T; Tatenuma T; Kawahara T; Ito Y; Komeya M; Muraoka K; Hasumi H; Uemura H; Makiyama K
    Int J Urol; 2024 Jun; 31(6):678-684. PubMed ID: 38402449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between comorbidities and survival in patients with metastatic urothelial carcinoma treated with pembrolizumab.
    Hashimoto M; Fukuokaya W; Yanagisawa T; Yamamoto S; Koike Y; Imai Y; Iwatani K; Onuma H; Ito K; Urabe F; Tsuzuki S; Kimura S; Oyama Y; Abe H; Miki J; Kimura T
    Int J Clin Oncol; 2024 May; 29(5):612-619. PubMed ID: 38430304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract.
    Sternberg CN; Loriot Y; James N; Choy E; Castellano D; Lopez-Rios F; Banna GL; De Giorgi U; Masini C; Bamias A; Garcia Del Muro X; Duran I; Powles T; Gamulin M; Zengerling F; Geczi L; Gedye C; de Ducla S; Fear S; Merseburger AS
    Eur Urol; 2019 Jul; 76(1):73-81. PubMed ID: 30910346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C-reactive Protein Is a Prognostic Factor for Survival in Metastatic Upper Tract Urothelial Carcinoma Patients Receiving Pembrolizumab.
    Nagasaka H; Yamamoto S; Suzuki A; Usui K; Terao H; Nakaigawa N; Kishida T
    In Vivo; 2024; 38(4):1823-1828. PubMed ID: 38936923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 project.
    Rizzo A; Buti S; Giannatempo P; Salah S; Molina-Cerrillo J; Massari F; Kopp RM; Fiala O; Galli L; Myint ZW; Tural D; Soares A; Pichler R; Mennitto A; Abahssain H; Calabrò F; Monteiro FSM; Albano A; Mollica V; Giudice GC; Takeshita H; Santoni M;
    Clin Exp Metastasis; 2024 Oct; 41(5):655-665. PubMed ID: 38850317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of radiotherapy to the primary tumor on the efficacy of pembrolizumab for patients with advanced urothelial cancer: A preliminary study.
    Fukushima H; Kijima T; Fukuda S; Moriyama S; Uehara S; Yasuda Y; Tanaka H; Yoshida S; Yokoyama M; Matsuoka Y; Saito K; Matsubara N; Numao N; Sakai Y; Yuasa T; Masuda H; Yonese J; Kageyama Y; Fujii Y
    Cancer Med; 2020 Nov; 9(22):8355-8363. PubMed ID: 32886446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response.
    Sundahl N; De Wolf K; Rottey S; Decaestecker K; De Maeseneer D; Meireson A; Goetghebeur E; Fonteyne V; Verbeke S; De Visschere P; Reynders D; Van Gele M; Brochez L; Ost P
    J Transl Med; 2017 Jun; 15(1):150. PubMed ID: 28662677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden.
    Srivastava T; Prabhu VS; Li H; Xu R; Zarabi N; Zhong Y; Pellissier JM; Perini RF; de Wit R; Mamtani R
    Eur Urol Oncol; 2020 Oct; 3(5):663-670. PubMed ID: 31412001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world epidemiology and treatment patterns of patients with locally advanced or metastatic urothelial carcinoma: Retrospective analysis of Diagnosis Procedure Combination claims data in Japan.
    Asakawa K; Waratani M; Massey O; Holbrook T; Kondo M; Saito A; Nishiyama H
    Int J Urol; 2024 Jul; 31(7):730-738. PubMed ID: 38468564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
    Powles T; Csőszi T; Özgüroğlu M; Matsubara N; Géczi L; Cheng SY; Fradet Y; Oudard S; Vulsteke C; Morales Barrera R; Fléchon A; Gunduz S; Loriot Y; Rodriguez-Vida A; Mamtani R; Yu EY; Nam K; Imai K; Homet Moreno B; Alva A;
    Lancet Oncol; 2021 Jul; 22(7):931-945. PubMed ID: 34051178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 Project.
    Rizzo A; Monteiro FSM; Ürün Y; Massari F; Park SH; Bourlon MT; Poprach A; Rizzo M; Takeshita H; Giannatempo P; Soares A; Roviello G; Molina-Cerrillo J; Carrozza F; Abahssain H; Messina C; Kopp RM; Pichler R; Formisano L; Tural D; Atzori F; Calabrò F; Kanesvaran R; Buti S; Santoni M
    Target Oncol; 2024 Sep; 19(5):747-755. PubMed ID: 39107651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial.
    Powles T; Chang YH; Yamamoto Y; Munoz J; Reyes-Cosmelli F; Peer A; Cohen G; Yu EY; Lorch A; Bavle A; Homet Moreno B; Markensohn J; Edmondson M; Chen C; Cristescu R; Peña C; Lunceford J; Gunduz S
    Nat Med; 2024 Sep; 30(9):2508-2516. PubMed ID: 38823511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.